WallStSmart

Merck & Company Inc (MRK)vsGeneDx Holdings Corp. (WGS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 14757% more annual revenue ($65.77B vs $442.68M). MRK leads profitability with a 13.6% profit margin vs -17.6%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 3.3Quality: 4.8
Piotroski: 2/9

WGS

Avoid

29

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 4.0Quality: 6.5
Piotroski: 6/9Altman Z: -2.39
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKOvervalued (-14.9%)

Margin of Safety

-14.9%

Fair Value

$97.76

Current Price

$111.38

$13.62 premium

UndervaluedFair: $97.76Overvalued
WGSSignificantly Overvalued (-54.0%)

Margin of Safety

-54.0%

Fair Value

$59.37

Current Price

$40.77

$18.60 premium

UndervaluedFair: $59.37Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$277.36B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

WGS1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
17.4%8/10

17.4% revenue growth

Areas to Watch

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
5.282/10

Expensive relative to growth rate

WGS4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.20B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-30.4%2/10

ROE of -30.4% — below average capital efficiency

Free Cash FlowQuality
$-38.86M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : WGS

The strongest argument for WGS centers on Revenue Growth. Revenue growth of 17.4% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Bear Case : WGS

The primary concerns for WGS are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while WGS is a growth play — different risk/reward profiles.

WGS carries more volatility with a beta of 2.07 — expect wider price swings.

WGS is growing revenue faster at 17.4% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

GeneDx Holdings Corp.

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Sema4 Holdings Corp. The company is headquartered in Stamford, Connecticut.

Visit Website →

Want to dig deeper into these stocks?